Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.35 |
| ▸ | DRD4 | P21917 | 5/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.35 |
| ▸ | HTR7 | P34969 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424772 | 1.00 | HTR1A (0.39) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8783440 | 0.85 | HTR1A (0.48) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8136251 | 0.85 | HTR1A (0.48) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8129133 | 0.85 | OPRM1 (0.46) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8543106 | 0.71 | OPRM1 (0.62) | HTR1ASMN1; SMN2LMNAADRA1ADRD4 | |
| SCHEMBL6429257 | 0.67 | HTR1A (0.47) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13533329 | 0.67 | OPRM1 (0.55) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13533328 | 0.67 | OPRM1 (0.55) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6546338 | 0.65 | HTR1A (0.72) | HTR1AMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL8120514 | 0.65 | HTR1A (0.42) | HTR1AMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026783-A2 | METHOD FOR ENHANCING COGNITIVE FUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007146073-A2 | METHOD FOR ENHANCING COGNITIVE FUNCTION | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | WYETH (US) | 2006-12-21 | — | — | US | claimed |
| EP-1534258-A2 | AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | Wyeth (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040063721-A1 | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction | WYETH | 2004-04-01 | — | — | US | claimed |
| WO-2004016256-A2 | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | WYETH (US) | 2004-02-26 | — | — | WO | claimed |
| EP-0763031-B1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | WYETH JOHN & BROTHER LTD (GB) | 2000-05-10 | — | — | EP | claimed |
| EP-0763031-A1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | JOHN WYETH & BROTHER LIMITED (GB) | 1997-03-19 | — | — | EP | claimed |
| WO-1995033743-A1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | JOHN WYETH & BROTHER LIMITED (GB) | 1995-12-14 | — | — | WO | claimed |
| EP-1971337-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7425558-B2 | -4-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin -1-yl)propy l)-N-pyridin-2-yl-benzamide or salts; 5-HT1A receptor antagonists; urinary incontinence | WYETH (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080070925-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH LLC | 2008-03-20 | — | — | US | disclosed |
| WO-2007081374-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060287333-A1 | Serotonergic agents for treating sexual dysfunction | WYETH (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | WYETH (US) | 2006-12-21 | — | — | US | disclosed |
| EP-1534258-A2 | AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | Wyeth (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063721-A1 | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction | WYETH | 2004-04-01 | — | — | US | disclosed |
| WO-2004016256-A2 | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | WYETH (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | HTR5A, HTR1A, HTR3A | HTR1A 2/4885MEN1 3526/4885KMT2A 3795/4885 |
| US-20060287333-A1 | Serotonergic agents for treating sexual dysfunction | HTR5A, HTR1A, HTR3A | HTR1A 2/4885MEN1 3526/4885KMT2A 3795/4885 |
| US-20080070925-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | HTR5A, HTR1A, HTR3A | HTR1A 2/4885MEN1 3526/4885KMT2A 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.